Amgen (AMGN) 154.78 $AMGN
New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression
PR Newswire - Fri Jun 10, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which highlighted the benefit of continued treatment with Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) in patients with relapsed multiple myeloma. Separate sub-analyses of the Phase 3 ENDEAVOR study further confirmed efficacy and depth of response benefits of Kyprolis plus dexamethasone (Kd). These results were presented at the 21st Congress of the European Hematology Association (EHA).
AMGN: 154.78 (-2.00)
Amgen Announces Expiration And Final Results Of Senior Notes Exchange Offers
PR Newswire - Fri Jun 10, 8:00AM CDT
Amgen (NASDAQ:AMGN) announced today the expiration and final results of its previously announced seven separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers"
certain specified series of its outstanding senior notes (collectively, the "Old Notes" for new 4.563% Senior Notes due 2048 (the "New 2048 Notes" and new 4.663% Senior Notes due 2051 (the "New 2051 Notes" and, together with the New 2048 Notes, the "New Notes", as applicable.
AMGN: 154.78 (-2.00)
Global Migraine Market Report: 2016 Edition Featuring Amgen, Teva Pharmaceuticals, Eli Lilly and Company & AstraZeneca - Research and Markets
BusinessWire - Fri Jun 10, 4:14AM CDT
Research and Markets has announced the addition of the "Global Migraine Market Report: 2016 Edition" report to their offering.
AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48)
BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
PR Newswire - Fri Jun 10, 1:30AM CDT
Amgen (NASDAQ:AMGN) today announced new data from a prespecified interim analysis of the Phase 3 TOWER study, in which BLINCYTO® (blinatumomab) demonstrated an almost two-fold increase in median overall survival (OS) compared to standard of care (SOC). The randomized, open-label TOWER study evaluated the efficacy of BLINCYTO versus SOC chemotherapy in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Results from the analysis showed that median OS was 7.7 months (95 percent CI: 5.6, 9.6) for BLINCYTO versus 4 months (95 percent CI: 2.9, 5.3) for SOC (stratified log-rank test p=.012; hazard ratio=0.71). As per the recommendation of an independent data monitoring committee, Amgen ended the study early for efficacy based on these results. The data will be presented during The Presidential Symposium at the 21st Congress of the European Hematology Association (EHA) in Copenhagen.
AMGN: 154.78 (-2.00)
Novartis (NVS) Announces Positive Results on Migraine Drug
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 5:22PM CDT
Novartis AG (NVS) reported positive first results from the global phase II study, 20120295 on pipeline candidate, AMG 334 (erenumab).
PFE: 35.29 (-0.02), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), NVS: 78.94 (-1.57)
Look for Shares of Amgen to Potentially Rebound after Yesterday's 1.18% Sell Off
Comtex SmarTrend(R) - Thu Jun 09, 12:23PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.00 to a high of $158.98. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $157.54 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 154.78 (-2.00)
Watch for Amgen to Potentially Rebound After Falling 1.18% Yesterday
Comtex SmarTrend(R) - Thu Jun 09, 12:21PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.00 to a high of $158.98. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $157.54 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 154.78 (-2.00)
Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine
PR Newswire - Wed Jun 08, 3:30PM CDT
Amgen (NASDAQ:AMGN) today announced positive top-line results from the global Phase 2 study evaluating the efficacy and safety of erenumab (AMG 334) in chronic migraine prevention. The study met its primary endpoint of change in monthly migraine days. The reduction in migraine days was statistically significant for both the 70 mg and 140 mg doses.
AMGN: 154.78 (-2.00)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 246.13 (-4.33), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), REGN: 372.03 (-9.05), CELG: 102.91 (-3.22)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), PXD: 159.55 (-4.65), ALXN: 135.61 (-2.63), HAL: 44.38 (-1.12), EOG: 81.56 (-3.02), AMGN: 154.78 (-2.00), ILMN: 141.62 (-1.80), XOM: 89.98 (-0.69), COP: 44.51 (-2.06), JUNO: 42.98 (-2.55), CVX: 101.98 (-0.83), OXY: 75.45 (-0.15), REGN: 372.03 (-9.05)
Next Support Level for Amgen (AMGN) is $158.08
Comtex SmarTrend(R) - Tue Jun 07, 8:43AM CDT
Shares of Amgen (NASDAQ:AMGN) have bearishly opened below the pivot of $159.94 today and have reached the first support level of $159.14. Should the shares continue to fall, the support pivots of $158.08 and $156.22 will be of interest.
AMGN: 154.78 (-2.00)
New National Survey Sheds Light On How To Better Engage Students In Science Education
PR Newswire - Tue Jun 07, 8:00AM CDT
The Amgen Foundation and Change the Equation (CTEq) today announced results of a survey conducted to better understand what motivates U.S. high school students to study science, technology, engineering and math (STEM). The report, titled "Students on STEM: More Hands-on, Real-World Experiences," shows that students want additional opportunities that will inspire them to explore careers in scientific fields, and teachers are uniquely positioned to stimulate students' interest in STEM.
AMGN: 154.78 (-2.00)
New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis® (Carfilzomib)-Based Regimen
PR Newswire - Mon Jun 06, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced data from a secondary analysis of the pivotal Phase 3 ASPIRE trial that showed Kyprolis® (carfilzomib) for Injection in combination with lenalidomide and dexamethasone (KRd) improved progression-free survival (PFS) and overall response rate (ORR) compared to lenalidomide and dexamethasone (Rd) alone in patients with relapsed multiple myeloma with early disease progression after initial therapy or transplant. The results were presented today at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO).
AMGN: 154.78 (-2.00)
Amgen Announces Launch Of KYPROLIS® (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers
PR Newswire - Fri Jun 03, 3:15PM CDT
Amgen (NASDAQ:AMGN) today announced the launch of KYPROLIS CENTRAL, an online media resource about the impact of living with relapsed or refractory multiple myeloma. Intended to drive awareness of a rare blood cancer that is increasingly becoming more prevalent in the United States (U.S.), KYPROLIS CENTRAL provides real-life stories from relapsed multiple myeloma patients, as well as educational materials and third party resources.1
AMGN: 154.78 (-2.00)
Amgen To Present At The Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Fri Jun 03, 3:00PM CDT
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 37th Annual Global Healthcare Conference at 1:20 p.m. PT on Tuesday, June 7, 2016, in Rancho Palos Verdes, Calif. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
AMGN: 154.78 (-2.00)
Biosimilars, PCSK9s, Value-Based Care Among Hot-Button Topics Tracked in New AIS Book
PRWeb - Fri Jun 03, 5:06AM CDT
Recently published by Atlantic Information Services, Inc. (AIS), Specialty Pharmacy Trends and Strategies: 2016-2017 Edition, tracks hot-button issues in the specialty pharmacy industry that will affect PBMs and insurers in 2016 and beyond, including the rise of biosimilars, PCSK9s and value-based initiatives: According to reporting in Specialty Pharmacy Trends and Strategies, Express Scripts, Inc. has estimated that Zarxio -- the first biosimilar approved by the Food and Drug Administration -- has the potential to save U.S. patients and payers $5.7 billion between 2014 and 2024 and additional drugs in the biosimilar pipeline could save an estimated $250 billion in savings over the next 10 years. But a lawsuit (Amgen Inc., Amgen Manufacturing Limited v. Sandoz Inc., No. 15-1499) raised several questions, including patent issues based on the language of the Biologics Price Competition and Innovation Act of the Affordable Care Act, and delayed Zarxio's launch. The book tracks the lawsuit and its implications, as well as the biosimilar space as whole, and provides historical background and future insight. Specialty Pharmacy Trends and Strategies also follows the impact of cholesterol-lowering PCSK9 inhibitors hitting the market, boasting costs $5,000 higher than industry insiders expected and causing pharmacy benefit managers to either balk at coverage or negotiate pay-for-performance deals with manufacturers. Cardiologists are excited for their potential, but health plans and PBMs have shown reluctance to fully embrace these super-statins. The book charts the implications for specialty pharmacy spend. One way payers are attempting to control costs of new drug innovations is the use of value-based initiatives, from bundled payments and other strategies in the oncology space to the use of quality-based pharmacy networks to drive better outcomes and thus lower prices. Specialty Pharmacy Trends and Strategies follows pilots and proposals undertaken by insurers, PBMs and the federal government to tie reimbursement and benefit design to more positive results for patients and payers.
ESRX: 75.91 (-1.02), AMGN: 154.78 (-2.00)
SCRS Announces the Site Study Dashboard Initiative in Collaboration with ARCO and Many Other Industry Stakeholders
PR Newswire - Wed Jun 01, 9:00AM CDT
The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, continues to ensure the site's voice is heard and positively influencing decisions of industry stakeholders announces the launch of Site Study Dashboard initiative. The following companies are participating: Allergan, Amgen, AstraZeneca, Bio Optronics (Clinical Conductor CTMS), Bristol-Myers Squibb, Center Point Clinical Services, Clinical Ink, Covance, DrugDev, EMD Serono, Fisher Clinical Services, goBalto, Greenphire, HealthCarePoint, INC Research, inVentiv Health, Janssen Pharmaceuticals, Lilly, Merck, Merge, Nimblify, Novartis, Oracle, PAREXEL, PPD, PRA, Quintiles, Regeneron Pharmaceuticals, Sanofi, Vertex and multiple sites from around the globe. This initiative will be co-chaired by representatives from Allergan, Quintiles and Apostle Clinical Trials.
AGN: 240.93 (-6.47), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), REGN: 372.03 (-9.05), NVS: 78.94 (-1.57)
Regeneron Reports Interim Data on Cholesterol Lowering Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:00AM CDT
Regeneron (REGN) presented positive interim data from a phase II proof-of-concept study on evinacumab for homozygous familial hypercholestrolemia.
ANIP: 52.05 (-1.64), AMGN: 154.78 (-2.00), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Enabling Technologies Consortium (ETC) Issues Request for Information (RFI) Regarding Development of Medium Throughput Personal Reactor Platform
PRWeb - Wed Jun 01, 2:29AM CDT
Parallel chemical reactor technology is used by scientists to test various reaction conditions, evaluate different substrates or reagents, or synthesize multiple analogs all at the same time during development of a drug substance process. This process can be made easier and more robust through the use of commercially available platforms, chosen primarily based upon the synthesis scale required (low vs. high volume), throughput needed (medium vs. high), and the level of training or expertise required (minimal vs. extensive). However, experience with and review of the currently available commercial technology have demonstrated that from all the permutations possible, the choices of suitable commercial platforms tend to be limited to either 1) easy to use high volume, low throughput or 2) complex, low volume, high throughput systems. These two experimental paradigms can be time and material intensive or require specialized staff to operate.
AMGN: 154.78 (-2.00)
New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression
PR Newswire - Fri Jun 10, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced results from a post-hoc analysis of the pivotal Phase 3 ASPIRE study which highlighted the benefit of continued treatment with Kyprolis® (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) in patients with relapsed multiple myeloma. Separate sub-analyses of the Phase 3 ENDEAVOR study further confirmed efficacy and depth of response benefits of Kyprolis plus dexamethasone (Kd). These results were presented at the 21st Congress of the European Hematology Association (EHA).
AMGN: 154.78 (-2.00)
Amgen Announces Expiration And Final Results Of Senior Notes Exchange Offers
PR Newswire - Fri Jun 10, 8:00AM CDT
Amgen (NASDAQ:AMGN) announced today the expiration and final results of its previously announced seven separate private offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers"
certain specified series of its outstanding senior notes (collectively, the "Old Notes" for new 4.563% Senior Notes due 2048 (the "New 2048 Notes" and new 4.663% Senior Notes due 2051 (the "New 2051 Notes" and, together with the New 2048 Notes, the "New Notes", as applicable. AMGN: 154.78 (-2.00)
Global Migraine Market Report: 2016 Edition Featuring Amgen, Teva Pharmaceuticals, Eli Lilly and Company & AstraZeneca - Research and Markets
BusinessWire - Fri Jun 10, 4:14AM CDT
Research and Markets has announced the addition of the "Global Migraine Market Report: 2016 Edition" report to their offering.
AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48)
BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
PR Newswire - Fri Jun 10, 1:30AM CDT
Amgen (NASDAQ:AMGN) today announced new data from a prespecified interim analysis of the Phase 3 TOWER study, in which BLINCYTO® (blinatumomab) demonstrated an almost two-fold increase in median overall survival (OS) compared to standard of care (SOC). The randomized, open-label TOWER study evaluated the efficacy of BLINCYTO versus SOC chemotherapy in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Results from the analysis showed that median OS was 7.7 months (95 percent CI: 5.6, 9.6) for BLINCYTO versus 4 months (95 percent CI: 2.9, 5.3) for SOC (stratified log-rank test p=.012; hazard ratio=0.71). As per the recommendation of an independent data monitoring committee, Amgen ended the study early for efficacy based on these results. The data will be presented during The Presidential Symposium at the 21st Congress of the European Hematology Association (EHA) in Copenhagen.
AMGN: 154.78 (-2.00)
Novartis (NVS) Announces Positive Results on Migraine Drug
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 5:22PM CDT
Novartis AG (NVS) reported positive first results from the global phase II study, 20120295 on pipeline candidate, AMG 334 (erenumab).
PFE: 35.29 (-0.02), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), NVS: 78.94 (-1.57)
Look for Shares of Amgen to Potentially Rebound after Yesterday's 1.18% Sell Off
Comtex SmarTrend(R) - Thu Jun 09, 12:23PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.00 to a high of $158.98. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $157.54 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 154.78 (-2.00)
Watch for Amgen to Potentially Rebound After Falling 1.18% Yesterday
Comtex SmarTrend(R) - Thu Jun 09, 12:21PM CDT
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $156.00 to a high of $158.98. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $157.54 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AMGN: 154.78 (-2.00)
Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine
PR Newswire - Wed Jun 08, 3:30PM CDT
Amgen (NASDAQ:AMGN) today announced positive top-line results from the global Phase 2 study evaluating the efficacy and safety of erenumab (AMG 334) in chronic migraine prevention. The study met its primary endpoint of change in monthly migraine days. The reduction in migraine days was statistically significant for both the 70 mg and 140 mg doses.
AMGN: 154.78 (-2.00)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 246.13 (-4.33), SRPT: 19.95 (-1.04), ALXN: 135.61 (-2.63), AMGN: 154.78 (-2.00), ABBV: 61.00 (+0.25), REGN: 372.03 (-9.05), CELG: 102.91 (-3.22)
Stock Market News for June 08, 2016
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:10AM CDT
Benchmarks closed mostly in the green on Tuesday following gains in energy stocks
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), PXD: 159.55 (-4.65), ALXN: 135.61 (-2.63), HAL: 44.38 (-1.12), EOG: 81.56 (-3.02), AMGN: 154.78 (-2.00), ILMN: 141.62 (-1.80), XOM: 89.98 (-0.69), COP: 44.51 (-2.06), JUNO: 42.98 (-2.55), CVX: 101.98 (-0.83), OXY: 75.45 (-0.15), REGN: 372.03 (-9.05)
Next Support Level for Amgen (AMGN) is $158.08
Comtex SmarTrend(R) - Tue Jun 07, 8:43AM CDT
Shares of Amgen (NASDAQ:AMGN) have bearishly opened below the pivot of $159.94 today and have reached the first support level of $159.14. Should the shares continue to fall, the support pivots of $158.08 and $156.22 will be of interest.
AMGN: 154.78 (-2.00)
New National Survey Sheds Light On How To Better Engage Students In Science Education
PR Newswire - Tue Jun 07, 8:00AM CDT
The Amgen Foundation and Change the Equation (CTEq) today announced results of a survey conducted to better understand what motivates U.S. high school students to study science, technology, engineering and math (STEM). The report, titled "Students on STEM: More Hands-on, Real-World Experiences," shows that students want additional opportunities that will inspire them to explore careers in scientific fields, and teachers are uniquely positioned to stimulate students' interest in STEM.
AMGN: 154.78 (-2.00)
New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis® (Carfilzomib)-Based Regimen
PR Newswire - Mon Jun 06, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced data from a secondary analysis of the pivotal Phase 3 ASPIRE trial that showed Kyprolis® (carfilzomib) for Injection in combination with lenalidomide and dexamethasone (KRd) improved progression-free survival (PFS) and overall response rate (ORR) compared to lenalidomide and dexamethasone (Rd) alone in patients with relapsed multiple myeloma with early disease progression after initial therapy or transplant. The results were presented today at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO).
AMGN: 154.78 (-2.00)
Amgen Announces Launch Of KYPROLIS® (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers
PR Newswire - Fri Jun 03, 3:15PM CDT
Amgen (NASDAQ:AMGN) today announced the launch of KYPROLIS CENTRAL, an online media resource about the impact of living with relapsed or refractory multiple myeloma. Intended to drive awareness of a rare blood cancer that is increasingly becoming more prevalent in the United States (U.S.), KYPROLIS CENTRAL provides real-life stories from relapsed multiple myeloma patients, as well as educational materials and third party resources.1
AMGN: 154.78 (-2.00)
Amgen To Present At The Goldman Sachs 37th Annual Global Healthcare Conference
PR Newswire - Fri Jun 03, 3:00PM CDT
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 37th Annual Global Healthcare Conference at 1:20 p.m. PT on Tuesday, June 7, 2016, in Rancho Palos Verdes, Calif. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
AMGN: 154.78 (-2.00)
Biosimilars, PCSK9s, Value-Based Care Among Hot-Button Topics Tracked in New AIS Book
PRWeb - Fri Jun 03, 5:06AM CDT
Recently published by Atlantic Information Services, Inc. (AIS), Specialty Pharmacy Trends and Strategies: 2016-2017 Edition, tracks hot-button issues in the specialty pharmacy industry that will affect PBMs and insurers in 2016 and beyond, including the rise of biosimilars, PCSK9s and value-based initiatives: According to reporting in Specialty Pharmacy Trends and Strategies, Express Scripts, Inc. has estimated that Zarxio -- the first biosimilar approved by the Food and Drug Administration -- has the potential to save U.S. patients and payers $5.7 billion between 2014 and 2024 and additional drugs in the biosimilar pipeline could save an estimated $250 billion in savings over the next 10 years. But a lawsuit (Amgen Inc., Amgen Manufacturing Limited v. Sandoz Inc., No. 15-1499) raised several questions, including patent issues based on the language of the Biologics Price Competition and Innovation Act of the Affordable Care Act, and delayed Zarxio's launch. The book tracks the lawsuit and its implications, as well as the biosimilar space as whole, and provides historical background and future insight. Specialty Pharmacy Trends and Strategies also follows the impact of cholesterol-lowering PCSK9 inhibitors hitting the market, boasting costs $5,000 higher than industry insiders expected and causing pharmacy benefit managers to either balk at coverage or negotiate pay-for-performance deals with manufacturers. Cardiologists are excited for their potential, but health plans and PBMs have shown reluctance to fully embrace these super-statins. The book charts the implications for specialty pharmacy spend. One way payers are attempting to control costs of new drug innovations is the use of value-based initiatives, from bundled payments and other strategies in the oncology space to the use of quality-based pharmacy networks to drive better outcomes and thus lower prices. Specialty Pharmacy Trends and Strategies follows pilots and proposals undertaken by insurers, PBMs and the federal government to tie reimbursement and benefit design to more positive results for patients and payers.
ESRX: 75.91 (-1.02), AMGN: 154.78 (-2.00)
SCRS Announces the Site Study Dashboard Initiative in Collaboration with ARCO and Many Other Industry Stakeholders
PR Newswire - Wed Jun 01, 9:00AM CDT
The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, continues to ensure the site's voice is heard and positively influencing decisions of industry stakeholders announces the launch of Site Study Dashboard initiative. The following companies are participating: Allergan, Amgen, AstraZeneca, Bio Optronics (Clinical Conductor CTMS), Bristol-Myers Squibb, Center Point Clinical Services, Clinical Ink, Covance, DrugDev, EMD Serono, Fisher Clinical Services, goBalto, Greenphire, HealthCarePoint, INC Research, inVentiv Health, Janssen Pharmaceuticals, Lilly, Merck, Merge, Nimblify, Novartis, Oracle, PAREXEL, PPD, PRA, Quintiles, Regeneron Pharmaceuticals, Sanofi, Vertex and multiple sites from around the globe. This initiative will be co-chaired by representatives from Allergan, Quintiles and Apostle Clinical Trials.
AGN: 240.93 (-6.47), AMGN: 154.78 (-2.00), BMY: 72.65 (-0.08), REGN: 372.03 (-9.05), NVS: 78.94 (-1.57)
Regeneron Reports Interim Data on Cholesterol Lowering Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 9:00AM CDT
Regeneron (REGN) presented positive interim data from a phase II proof-of-concept study on evinacumab for homozygous familial hypercholestrolemia.
ANIP: 52.05 (-1.64), AMGN: 154.78 (-2.00), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
Enabling Technologies Consortium (ETC) Issues Request for Information (RFI) Regarding Development of Medium Throughput Personal Reactor Platform
PRWeb - Wed Jun 01, 2:29AM CDT
Parallel chemical reactor technology is used by scientists to test various reaction conditions, evaluate different substrates or reagents, or synthesize multiple analogs all at the same time during development of a drug substance process. This process can be made easier and more robust through the use of commercially available platforms, chosen primarily based upon the synthesis scale required (low vs. high volume), throughput needed (medium vs. high), and the level of training or expertise required (minimal vs. extensive). However, experience with and review of the currently available commercial technology have demonstrated that from all the permutations possible, the choices of suitable commercial platforms tend to be limited to either 1) easy to use high volume, low throughput or 2) complex, low volume, high throughput systems. These two experimental paradigms can be time and material intensive or require specialized staff to operate.
AMGN: 154.78 (-2.00)
